Co-transplantation of GDNF-overexpressing neural stem cells and fetal dopaminergic neurons mitigates motor symptoms in a rat model of parkinson's disease

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Deng, Xingli ^a   Liang, Yuanxin ^b   Lu, Hua ^a   Yang, Zhiyong ^a   Liu, RU'En ^c   Wang, Jinkun ^a   Song, Xiaobin ^a   Long, Jiang ^a   Li, Yu ^a   Lei, Deqiang ^d   Feng, Zhongtang ^a  

^a KUNMING MEDICAL UNIVERSITY   (China)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

^d HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ENHANCED GREEN FLUORESCENT PROTEIN; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; SUPERPARAMAGNETIC IRON OXIDE; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CELL DIFFERENTIATION; CELL ISOLATION; CELL MIGRATION; CELL SURVIVAL; CELL TRANSPLANTATION; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; FETUS; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MOTOR DYSFUNCTION; NEURAL STEM CELL; NONHUMAN; PARKINSON DISEASE; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSMISSION ELECTRON MICROSCOPY; VENTRAL TEGMENTUM; WESTERN BLOTTING;

ALLOGRAFTS; ANIMALS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DOPAMINERGIC NEURONS; FETUS; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; HUMANS; MOTOR ACTIVITY; NEURAL STEM CELLS; PARKINSON DISEASE; RATS; RATS, SPRAGUE-DAWLEY; STEM CELL TRANSPLANTATION;

EID: 84891810028     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0080880     Document Type: Article

References (34)

1. Eriksen JL, Wszolek Z, Petrucelli L (2005) Molecular pathogenesis of Parkinson disease. Arch Neurol 62(3): 353-357.
2. Fahn S (2006) Levodopa in the treatment of Parkinson's disease. J Neural Transm Suppl (71): 1-15.
3. Paul G, Ahn YH, Li JY, Brundin P (2006) Transplantation in Parkinson's disease: The future looks bright. Adv Exp Med Biol 557: 221-248.
4. Kim HT, Kim IS, Lee IS, Lee JP, Snyder EY, et al (2006) Human neurospheres derived from the fetal central nervous system are regionally and temporally specified but are not committed. Exp Neurol 199(1): 222-235.
5. Storch A, Sabolek M, Milosevic J, Schwarz SC, Schwarz J (2004) Midbrain-derived neural stem cells: from basic science to therapeutic approaches. Cell Tissue Res 318(1): 15-22.
6. Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F (1993) GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260(5111): 1130-1132.
7. Grondin R, Gash DM (1998) Glial cell line-derived neurotrophic factor (GDNF): a drug candidate for the treatment of Parkinson's disease. J Neurol 245(11 Suppl 3): P35-P42.
8. Moukhles H, Amalric M, Nieoullon A, Daszuta A (1994) Behavioural recovery of rats grafted with dopamine cells after partial striatal dopaminergic depletion in a conditioned reaction-time task. Neuroscience 63(1): 73-84.
9. Wang Z, Andrade N, Torp M, Wattananit S, Arvidsson A, et al (2012) Meteorin is a chemokinetic factor in neuroblast migration and promotes stroke-induced striatal neurogenesis. J Cereb Blood Flow Metab 32(2): 387-398.
10. Freed CR, Leehey MA, Zawada M, Bjugstad K, Thompson L, et al (2003) Do patients with Parkinson's disease benefit from embryonic dopamine cell transplantation? J Neurol 250 Suppl 3: III44-46.
11. Cesaro P (2004) The design of clinical trials for cell transplantation into the central nervous system. NeuroRx 1(4): 492-499.
12. Bjorklund A (2005) Cell therapy for Parkinson's disease: problems and prospects. Novartis Found Symp 265: 174-186; discussion 187, 204-211.
13. Winkler C, Kirik D, Bjorklund A (2005) Cell transplantation in Parkinson's disease: how can we make it work? Trends Neurosci 28(2): 86-92.
14. Brundin P, Karlsson J, Emgard M, Schierle GS, Hansson O, et al (2000) Improving the survival of grafted dopaminergic neurons: a review over current approaches. Cell Transplant 9(2): 179-195.
15. Nikkhah G, Rosenthal C, Falkenstein G, Roedter A, Papazoglou A, et al (2009) Microtransplantation of dopaminergic cell suspensions: further characterization and optimization of grafting parameters. Cell Transplant 18(2): 119-133.
16. Shimoda K, Sauve Y, Marini A, Schwartz JP, Commissiong JW (1992) A high percentage yield of tyrosine hydroxylase-positive cells from rat E14 mesencephalic cell culture. Brain Res 586(2): 319-331.
17. Bazán E, Alonso FJ, Redondo C, López-Toledano MA, Alfaro JM, et al (2004) In vitro and in vivo characterization of neural stem cells. Histol Histopathol 19(4): 1261-1275.
18. Lee MK, Tuttle JB, Rebhun LI, Cleveland DW, Frankfurter A (1990) The expression and posttranslational modification of a neuron-specific beta-tubulin isotype during chick embryogenesis. Cell Motil Cytoskeleton 17: 118-132.
19. Molofsky AV, Krenick R, Ullian E, Tsai H, Deneen B, et al (2012) Astrocytes and disease: a neurodevelopmental perspective. Genes Dev 26(9): 891-907.
20. Haavik J, Toska K (1998) Tyrosine hydroxylase and Parkinson's disease. Mol Neurobiol 16(3): 285-309.
21. Thorek DL, Chen AK, Czupryna J, Tsourkas A, Chen AK, et al (2006) Superparamagnetic iron oxide nanoparticle probes for molecular imaging. Ann Biomed Eng 34(1): 23-38.
22. Rogers WJ, Meyer CH, Kramer CM (2006) Technology insight: in vivo cell tracking by use of MRI. Nat Clin Pract Cardiovasc Med 3(10): 554-562.
23. Yuan H, Sarre S, Ebinger G, Michotte Y (2005) Histological, behavioural and neurochemical evaluation of medial forebrain bundle and striatal 6-OHDA lesions as rat models of Parkinson's disease. J Neurosci Methods 144(1): 35-45.
24. Dezawa M, Kanno H, Hoshino M, Cho H, Matsumoto N (2004) Specific induction of neuronal cells from bone marrow stromal cells and application for autologous transplantation. J Clin Invest 113(12): 1701-1710.
25. Li F, Wang M, Zhu S, Li L, Xiong Y, et al (2013) The potential neuroprotection mechanism of GDNF in the 6-OHDA-induced cellular models of Parkinson's disease. Cell Mol Neurobiol 33(7): 907-919.
26. Sun Y, Huang X, Liu M, Cao J, Chen J, et al (2012) A new alternative NF- 〈kappa〉 B pathway mediated the neuroprotection of GDNF on 6-OHDA-induced DA neurons neurotoxicity. Brain Res 1437: 38249.
27. Tomac A, Lindqvist E, Lin LF, Ogren SO, Young D, et al (1995) Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 373(6512): 335-339.
28. Nutt JG, Burchiel KJ, Comella CL, Jankovic J, Lang AE, et al (2003) Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 60(1): 69-73.
29. Kirik D, Georgievska B, Bjorklund A (2004) Localized striatal delivery of GDNF as a treatment for Parkinson disease. Nat Neurosci 7(2): 105-110.
30. Kordower JH (2003) In vivo gene delivery of glial cell line-derived neurotrophic factor for Parkinson's disease. Ann Neurol 53 (Suppl 3): S120-132; discussion S132-134.
31. Willenbrock S, Knippenberg S, Meier M, Hass R, Wefstaedt P, et al (2012) In vivo MRI of intraspinally injected SPIO-labelled human CD34+ cells in a transgenic mouse model of ALS. In vivo 26(1): 31-38.
32. Jin G, Tan X, Tian M, Qin J, Zhu H, et al (2005) The controlled differentiation of human neural stem cells into TH-immunoreactive (ir) neurons in vitro. Neurosci Lett 386(2): 105-110.
33. Haas SJ, Beckmann S, Petrov S, Andressen C, Wree A, et al (2007) Transplantation of immortalized mesencephalic progenitors (CSM14.1 cells) into the neonatal parkinsonian rat caudate putamen. J Neurosci Res 85(4): 778-786.
34. Brundin P, Karlsson J, Emgard M, Schierle GS, Hansson O, et al (2000) Improving the survival of grafted dopaminergic neurons: a review over current approaches. Cell Transplant 9(2): 1792195.